Drs. Rafael Bejar (San Diego) and Moshe Mittelman (Tel Aviv) discuss several papers highlighting the role of genetics in MDS diagnosis, follow up and prediction of treatment. They also discuss the role of the newly approved luspatercept in the treatment of anemic transfusion-dependent patients with lower-risk MDS
If you have questions or feedback on this podcast, please feel free to contact us. We would love to hear from you!
Enjoying Our Podcasts?
If you are enjoying our podcasts and other resources, please consider becoming a Professional Member of the MDS Foundation.
Learn More About Membership